TGFB1 and hepatocellular carcinoma: The cytotoxic effects of two SFK inhibitors—saracatinib and dasatinib—were assessed using the MTT assay in different cell lines, including HCC subtype S1/TGFβ-Wnt (HLE, HLF, and JHH6), HCC subtype S2/progenitor subtype (Huh7 and HepG2), and immortalized hepatocytes (IHHs) [6].